US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Seaport Therapeutics (SPTX): Strong Syndicate, Mid-Stage Pipeline Drive IPO Momentum

Seaport Therapeutics (SPTX): Strong IPO Demand Meets Profit Taking in Seaport Debut

Seaport Therapeutics (SPTX): Peeking at the IPO Prospectus of Biotech Dealing with Depression

IPOs and Secondary Offerings

Equity Capital Markets

Seaport Therapeutics / Equity Capital Markets

<ul>
<li>Seaport Therapeutics (SPTX) targets ~$200M IPO, offering 11.8M shares at $16–$18, implying ~$811M–$912M market cap ahead of May 1 debut.</li>
<li>Lead asset GlyphAllo in Phase 2b for depression; pipeline advancing with GlyphAgo and earlier-stage programs targeting large neuropsychiatric markets.</li>
<li>Strong backing from PureTech Health and ARCH Venture Partners, though Phase 2 stage may temper demand versus recent Phase 3 IPO peers.</li>
</ul>


Seaport Therapeutics (SPTX) targets ~$200M IPO, offering 11.8M shares at $16–$18, implying ~$811M–$912M market cap ahead of May 1 debut.
Lead asset GlyphAllo in Phase 2b for depression; pipeline advancing with GlyphAgo and earlier-stage programs targeting large neuropsychiatric markets.
Strong backing from PureTech Health and ARCH Venture Partners, though Phase 2 stage may temper demand versus recent Phase 3 IPO peers.


シーポート・セラピューティクス（SPTX）：2億ドルの新規株式公開（IPO）で、抗うつ薬パイプラインが市場に登場